Overview

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Changzhou Cancer Hospital of Soochow University